Rivoceranib plus Camrelizumab for First-Line Treatment of HCC: Data from CARES-310

Rachna Shroff, MD, MS, FASCO, shares data from the CARES-310 study showing improved progression-free and overall survival in patients with hepatocellular carcinoma treated with camrelizumab and rivoceranib compared to sorafenib, regardless of liver function.

Related Keywords

Rachna Shroff , ,Assessing Liver Function ,First Line Treatment ,Hcc ,Hepatocellular Carcinoma ,Liver Function ,Patients With Hcc ,Patients With Hepatocellular Carcinoma ,Liver Function Assessments ,Assessing Liver Function In Patients ,Risk Factors Hepatocellular Carcinoma ,Liver Function Hepatocellular Carcinoma ,Hepatocellular Carcinoma Treatments ,